Pfizer (PFE) Non-Current Debt (2009 - 2026)
Pfizer (PFE) reported Non-Current Debt of $60.6 billion for Q1 2026, up 5.08% year-over-year from $57.6 billion in Q1 2025, and down 1.75% on a QoQ basis from $61.6 billion in Q4 2025.
Pfizer (PFE) has 18 years of Non-Current Debt data on file, last reported at $60.6 billion in Q1 2026.
- Quarterly Non-Current Debt rose 5.08% year-over-year to $60.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.6 billion (up 5.08% YoY) and the FY2025 annual result came in at $61.6 billion, up 8.14% from the prior year.
- Non-Current Debt fell to $60.6 billion in Q1 2026 per PFE's latest filing, from $61.6 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $61.6 billion in Q4 2025 and bottomed at $31.7 billion in Q2 2023.
- The 5-year median for Non-Current Debt is $57.5 billion (2024), against an average of $51.7 billion.
- The widest annual swing landed in 2023, when Non-Current Debt decreased 11.08%; it then jumped 93.37% in 2024.
- Tracing PFE's Non-Current Debt over 5 years: stood at $32.9 billion in 2022, then jumped by 87.14% to $61.5 billion in 2023, then decreased by 7.37% to $57.0 billion in 2024, then climbed by 8.14% to $61.6 billion in 2025, then dropped by 1.75% to $60.6 billion in 2026.
- Per Business Quant, the three latest PFE Non-Current Debt figures stand at $60.6 billion (Q1 2026), $61.6 billion (Q4 2025), and $57.4 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 39.37 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 37.53 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 46.67 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 51.89 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 20.86 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 60.57 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 42.15 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 19.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 60.57 Bn |
| Mar 29, 2026 | 60.57 Bn |
| Dec 31, 2025 | 61.64 Bn |
| Dec 31, 2025 | 61.64 Bn |
| Sep 28, 2025 | 57.41 Bn |
| Sep 28, 2025 | 57.41 Bn |
| Jun 29, 2025 | 57.50 Bn |
| Jun 29, 2025 | 57.50 Bn |
| Mar 30, 2025 | 57.64 Bn |
| Mar 30, 2025 | 57.64 Bn |
| Dec 31, 2024 | 57.00 Bn |
| Dec 31, 2024 | 57.00 Bn |
| Sep 29, 2024 | 58.00 Bn |
| Sep 29, 2024 | 58.00 Bn |
| Jun 30, 2024 | 57.51 Bn |
| Jun 30, 2024 | 57.51 Bn |
| Mar 31, 2024 | 61.31 Bn |
| Mar 31, 2024 | 61.31 Bn |
| Dec 31, 2023 | 61.54 Bn |
| Dec 31, 2023 | 61.54 Bn |
| Oct 1, 2023 | 61.05 Bn |
| Oct 1, 2023 | 61.05 Bn |
| Jul 2, 2023 | 61.36 Bn |
| Jul 2, 2023 | 61.36 Bn |
| Apr 2, 2023 | 31.70 Bn |
| Apr 2, 2023 | 31.70 Bn |
| Dec 31, 2022 | 32.88 Bn |
| Dec 31, 2022 | 32.88 Bn |
| Oct 2, 2022 | 32.63 Bn |
| Oct 2, 2022 | 32.63 Bn |
| Jul 3, 2022 | 34.29 Bn |
| Jul 3, 2022 | 34.29 Bn |
| Apr 3, 2022 | 35.66 Bn |
| Apr 3, 2022 | 35.66 Bn |
| Dec 31, 2021 | 36.00 Bn |
| Dec 31, 2021 | 36.00 Bn |
| Oct 3, 2021 | 36.25 Bn |
| Oct 3, 2021 | 36.25 Bn |
| Jul 4, 2021 | 35.35 Bn |
| Jul 4, 2021 | 35.35 Bn |
| Apr 4, 2021 | 35.35 Bn |
| Apr 4, 2021 | 35.35 Bn |
| Dec 31, 2020 | 37.13 Bn |
| Dec 31, 2020 | 37.13 Bn |
| Sep 27, 2020 | 49.79 Bn |
| Sep 27, 2020 | 49.79 Bn |
| Jun 28, 2020 | 50.53 Bn |
| Jun 28, 2020 | 50.53 Bn |
| Mar 29, 2020 | 36.28 Bn |
| Mar 29, 2020 | 36.28 Bn |
| Dec 31, 2019 | 35.96 Bn |
| Dec 31, 2019 | 35.96 Bn |
| Sep 29, 2019 | 36.04 Bn |
| Sep 29, 2019 | 36.04 Bn |
| Jun 30, 2019 | 36.17 Bn |
| Jun 30, 2019 | 36.17 Bn |
| Mar 31, 2019 | 35.73 Bn |
| Mar 31, 2019 | 35.73 Bn |
| Dec 31, 2018 | 32.91 Bn |
| Dec 31, 2018 | 32.91 Bn |
| Sep 30, 2018 | 33.65 Bn |
| Sep 30, 2018 | 33.65 Bn |
| Jul 1, 2018 | 28.94 Bn |
| Jul 1, 2018 | 28.94 Bn |
| Apr 1, 2018 | 31.83 Bn |
| Apr 1, 2018 | 31.83 Bn |
| Dec 31, 2017 | 33.54 Bn |
| Dec 31, 2017 | 33.54 Bn |
| Oct 1, 2017 | 34.50 Bn |
| Oct 1, 2017 | 34.50 Bn |
| Jul 2, 2017 | 34.19 Bn |
| Jul 2, 2017 | 34.19 Bn |
| Apr 2, 2017 | 36.33 Bn |
| Apr 2, 2017 | 36.33 Bn |
| Dec 31, 2016 | 31.40 Bn |
| Dec 31, 2016 | 31.40 Bn |
| Oct 2, 2016 | 30.44 Bn |
| Oct 2, 2016 | 30.44 Bn |
| Jul 3, 2016 | 30.46 Bn |
| Jul 3, 2016 | 30.46 Bn |
| Apr 3, 2016 | 27.82 Bn |
| Apr 3, 2016 | 27.82 Bn |
| Dec 31, 2015 | 28.74 Bn |
| Dec 31, 2015 | 28.74 Bn |
| Sep 27, 2015 | 29.08 Bn |
| Sep 27, 2015 | 29.08 Bn |
| Jun 28, 2015 | 26.73 Bn |
| Jun 28, 2015 | 26.73 Bn |
| Mar 29, 2015 | 29.37 Bn |
| Mar 29, 2015 | 29.37 Bn |
| Dec 31, 2014 | 31.54 Bn |
| Dec 31, 2014 | 31.54 Bn |
| Sep 28, 2014 | 31.67 Bn |
| Sep 28, 2014 | 31.67 Bn |
| Jun 29, 2014 | 32.27 Bn |
| Jun 29, 2014 | 32.27 Bn |
| Mar 30, 2014 | 27.65 Bn |
| Mar 30, 2014 | 27.65 Bn |
| Dec 31, 2013 | 30.46 Bn |
| Dec 31, 2013 | 30.46 Bn |
| Sep 29, 2013 | 31.81 Bn |
| Sep 29, 2013 | 31.81 Bn |
| Jun 30, 2013 | 31.53 Bn |
| Jun 30, 2013 | 31.53 Bn |
| Mar 31, 2013 | 31.48 Bn |
| Mar 31, 2013 | 31.48 Bn |
| Dec 31, 2012 | 31.04 Bn |
| Dec 31, 2012 | 31.04 Bn |
| Sep 30, 2012 | 31.08 Bn |
| Sep 30, 2012 | 31.08 Bn |
| Jul 1, 2012 | 30.87 Bn |
| Jul 1, 2012 | 30.87 Bn |
| Apr 1, 2012 | 33.54 Bn |
| Apr 1, 2012 | 33.54 Bn |
| Dec 31, 2011 | 34.93 Bn |
| Dec 31, 2011 | 34.93 Bn |
| Oct 2, 2011 | 35.40 Bn |
| Oct 2, 2011 | 35.40 Bn |
| Jul 3, 2011 | 35.72 Bn |
| Jul 3, 2011 | 35.72 Bn |
| Apr 3, 2011 | 35.31 Bn |
| Apr 3, 2011 | 35.31 Bn |
| Dec 31, 2010 | 38.41 Bn |
| Dec 31, 2010 | 38.41 Bn |
| Oct 3, 2010 | 39.01 Bn |
| Oct 3, 2010 | 39.01 Bn |
| Jul 4, 2010 | 37.77 Bn |
| Jul 4, 2010 | 37.77 Bn |
| Apr 4, 2010 | 38.28 Bn |
| Apr 4, 2010 | 38.28 Bn |
| Dec 31, 2009 | 43.19 Bn |
| Dec 31, 2009 | 43.19 Bn |
| Sep 27, 2009 | 32.40 Bn |
| Sep 27, 2009 | 32.40 Bn |
| Jun 28, 2009 | 31.86 Bn |
| Jun 28, 2009 | 31.86 Bn |